A Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2013
At a glance
- Drugs Milatuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2009 Planned number of patients changed from 66 to 78 as reported by M.D. Anderson Cancer Center.